- Trial phase
- Phase 1/2
- Time to market
- At least 4-6 years away. The drug is in Phase 1/2 with no pivotal trial yet initiated. If the year-end 2026 update is positive, a Phase 3 trial could start in 2027-2028, with potential approval in the 2030-2032 timeframe, assuming success.
- Why 2/10
- The next catalyst is a program update expected by year-end 2026 (Q4 2026), which is a soft milestone rather than a hard binary event like a PDUFA or pivotal readout. BMN 351 is an early Phase 1/2 program at a large diversified biotech with over $1B in quarterly revenue, so this single drug represents a very small fraction of BioMarin's enterprise value. ImpactScore is 2.
Watch for BioMarin's year-end 2026 program update on BMN 351, which is expected to include clinical data from the 6 mg/kg and 9 mg/kg cohorts of the Phase 1/2 study. Positive dystrophin expression data could support advancement to a pivotal trial, while any safety signal or disappointing efficacy would be a setback. However, given BMN 351's small weight in BioMarin's diversified portfolio, even a clear outcome is unlikely to move the stock more than a few percent.
Price Chart
Executive Summary
BMN 351 (nivudirsen) is BioMarin's Phase 1/2 antisense oligonucleotide therapy for Duchenne muscular dystrophy (DMD) patients with genetic mutations amenable to exon 51 skipping, representing roughly 13% of the DMD population. Initial Phase 1/2 data showed 5.0% mean absolute dystrophin expression at week 25 in the 9 mg/kg cohort with acceptable safety, and the company expects to provide a program update by year-end 2026. The drug faces entrenched competition from Sarepta's already-approved Exondys 51 (eteplirsen), though Sarepta's next-generation SRP-5051 was discontinued in 2024 over safety concerns. For BioMarin, a diversified rare-disease company that just posted its first $1B+ revenue quarter, BMN 351 is a small early-stage pipeline asset with limited near-term stock impact potential.
How It Works
BMN 351 is an antisense oligonucleotide (a short, lab-made piece of genetic material) designed to treat Duchenne muscular dystrophy (DMD) in patients with a specific genetic mutation. DMD is caused by a lack of the protein dystrophin, which muscles need to stay intact. BMN 351 works by 'skipping over' a faulty section (exon 51) of the dystrophin gene during protein production, allowing cells to produce a shortened but still functional version of dystrophin. This is similar to the naturally occurring, milder form of the disease called Becker muscular dystrophy. The drug is given as a weekly intravenous infusion.
Trial Status
The Phase 1/2 study (351-201, NCT06280209) is an open-label, dose-escalation trial in ambulatory boys aged 4-10 with DMD amenable to exon 51 skipping. Interim data through 25 weeks showed acceptable safety and positive dystrophin changes. A Phase 2 open-label extension study (NCT07573631) is also recruiting to assess long-term safety and functional efficacy. BioMarin expects to share a clinical update for the 6 mg/kg and 9 mg/kg cohorts by year-end 2026.
The Two-Sided Case
Upcoming Catalysts
- Program update by year-end 2026 (Q4 2026): clinical data from the 6 mg/kg and 9 mg/kg cohorts of the Phase 1/2 study
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report